Latest news with #McKessonCorporation
Business Wire
11 hours ago
- Business
- Business Wire
McKesson to Host Investor Day on September 23, 2025
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced it will host an Investor Day on Tuesday, September 23, 2025, in New York City. The event will feature presentations by McKesson's leadership team followed by a Q&A session with chief executive officer Brian Tyler and chief financial officer Britt Vitalone. Management will provide an update on the company's strategic priorities, growth strategies, and business outlook. A live webcast of the event and replay, along with the company's slide presentation will be available on McKesson's Investor Relations website at where you can find a complete listing of upcoming events, including details and updates. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at and read Our Stories.
Business Wire
03-06-2025
- Business
- Business Wire
McKesson Corporation Completes Acquisition of Core Ventures
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) announced today that it has completed the acquisition of a controlling interest in Community Oncology Revitalization Enterprise Ventures, LLC (Core Ventures), a business and administrative services organization established by Florida Cancer Specialists & Research Institute, LLC (FCS). The acquisition advances community-based oncology care and enables McKesson to continue to accelerate clinical development, improve patient outcomes, and expand access to quality cancer care in local communities. McKesson acquired an approximate 70% controlling interest in Core Ventures for about $2.49 billion. FCS physicians retained an approximate 30% interest. FCS, a practice with more than 250 physicians and 280 advanced practice providers, across nearly 100 locations in Florida, remains independently owned and became a member of McKesson's The US Oncology Network, a leading oncology organization, dedicated to advancing local and affordable cancer care and better patient outcomes. Cautionary Statement Except for historical information, statements in this press release regarding McKesson's acquisition and related arrangements constitute 'forward-looking statements' within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, that involve risks and uncertainties that could cause actual results to differ materially from those in those statements. It is not possible to identify all such risks and uncertainties. The reader should not place undue reliance on forward-looking statements, which speak only as of the date they are first made. Except to the extent required by law, the company undertakes no obligation to publicly update forward-looking statements. We encourage investors to read the important risk factors described in the company's most recent Form 10-K filed with the Securities and Exchange Commission. These risk factors include, but are not limited to: we may not achieve expected outcomes from the transaction; we from time to time record significant charges from impairment to goodwill, intangibles and other assets or investments; we might be adversely impacted by events outside of our control, such as widespread public health issues, natural disasters, political events, economic events and other catastrophic events. About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at and read Our Stories. About McKesson Oncology and Specialty Solutions It's an unprecedented time for patients living with cancer as life sciences companies race to create new, cutting-edge therapies. With cancer care becoming more targeted, providers, life sciences companies, and payers face a multitude of challenges and complexity in the development of new treatments and making them accessible to patients in need. At McKesson, our unmatched portfolio of oncology businesses and partners provide research, insights, technologies, and services that are helping to address these hurdles and improve cancer and specialty care. McKesson is fueling discovery by helping patients participate in cutting-edge clinical trials closer to home through its joint venture with Sarah Cannon Research Institute. The US Oncology Network and McKesson Provider Solutions are advancing specialty care and high-quality cancer care in the communities where patients live by supporting the practices of thousands of independent, community-based providers. Ontada ®, a McKesson business dedicated to oncology, generates real-world data (RWD) and real-world evidence (RWE), and provides clinical education and provider technology to inform and improve cancer care. As one of the largest distributors of oncology and specialty medicines, we are ensuring medicines make their way to those who are counting on them. And through CoverMyMeds, Biologics by McKesson, and GPO services, our work continues to help patients access, afford, and adhere to their medicines.
Yahoo
12-05-2025
- Business
- Yahoo
Here's Why Baron Health Care Fund Reacquired McKesson Corporation (MCK) in Q1
Baron Funds, an investment management company, released its 'Baron Health Care Fund' first quarter 2025 investor letter. A copy of the letter can be downloaded here. The fund returned 2.54% (Institutional Shares) in the quarter compared to a 3.87% gain for the Russell 3000 Health Care Index (benchmark) and a 4.72% decline for the Russell 3000 Index (the Index). The fund trailed the benchmark due to stock selection and, to a lesser extent, active sub-industry weights. In addition, please check the fund's top five holdings to know its best picks in 2025. In its first-quarter 2025 investor letter, Baron Health Care Fund highlighted stocks such as McKesson Corporation (NYSE:MCK). McKesson Corporation (NYSE:MCK) offers healthcare services through U.S. Pharmaceutical, Prescription Technology Solutions (RxTS), Medical-Surgical Solutions, and International segments. The one-month return of McKesson Corporation (NYSE:MCK) was 0.07%, and its shares gained 25.04% of their value over the last 52 weeks. On May 9, 2025, McKesson Corporation (NYSE:MCK) stock closed at $693.46 per share with a market capitalization of $86.683 billion. Baron Health Care Fund stated the following regarding McKesson Corporation (NYSE:MCK) in its Q1 2025 investor letter: "Minimally offsetting the above was strength in health care distributors attributable to a combination of stock selection and active exposure to this strong performing sub-industry. Recent addition McKesson Corporation (NYSE:MCK), a leading distributor of pharmaceutical/medical supplies and provider of prescription technology solutions that connect pharmacies, providers, payers, and biopharmaceutical customers, led the way in health care distributors. We discuss why we re-established a position in McKesson in the Recent Activity section below. A successful pharmacist in front of shelves of drugs in a community-based oncology pharmacy. McKesson Corporation (NYSE:MCK) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 78 hedge fund portfolios held McKesson Corporation (NYSE:MCK) at the end of the fourth quarter compared to 57 in the third quarter. While we acknowledge the potential of McKesson Corporation (NYSE:MCK) as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns, and doing so within a shorter timeframe. If you are looking for an AI stock that is as promising as NVIDIA but that trades at less than 5 times its earnings, check out our report about the cheapest AI stock. In another article, we covered McKesson Corporation (NYSE:MCK) and shared the list of Jim Cramer recently discussed. In addition, please check out our hedge fund investor letters Q1 2025 page for more investor letters from hedge funds and other leading investors. READ NEXT: Michael Burry Is Selling These Stocks and A New Dawn Is Coming to US Stocks. Disclosure: None. This article is originally published at Insider Monkey.
Business Wire
08-05-2025
- Business
- Business Wire
McKesson Reports Fiscal 2025 Fourth Quarter and Full Year Results
IRVING, Texas--(BUSINESS WIRE)--McKesson Corporation (NYSE: MCK) has released its fiscal 2025 fourth quarter financial results. Results can be accessed on McKesson's Investor Relations website at As previously announced, the company will host a live webcast of the earnings conference call for investors today, Thursday, May 8 th at 4:30 PM ET to review its financial results. The audio webcast of the conference call will be available live and archived on McKesson's Investor Relations website, along with the company's earnings press release, financial tables, and slide presentation. Additional information about upcoming events for the investor community can be found at About McKesson Corporation McKesson Corporation is a diversified healthcare services leader dedicated to advancing health outcomes for patients everywhere. Our teams partner with biopharma companies, care providers, pharmacies, manufacturers, governments, and others to deliver insights, products and services to help make quality care more accessible and affordable. Learn more about how McKesson is impacting virtually every aspect of healthcare at and read Our Stories.
Yahoo
07-05-2025
- Business
- Yahoo
Jim Cramer on McKesson Corporation (MCK): ‘Defying Doubters as a Middleman Money Machine'
We recently published a list of Jim Cramer Reveals Trump's Potential Secret Weapon In China Trade Talks & Discusses These 10 Stocks. In this article, we are going to take a look at where McKesson Corporation (NYSE:MCK) stands against other stocks that Jim Cramer recently discussed. In a recent appearance on CNBC's Squawk on the Street, Jim Cramer discussed the impacts that tariffs have had on businesses. He shared that firms are scrambling to diversify their supply chains from China as higher costs affect business margins. Using the example of the firm known for making Monopoly and Nerf, Cramer commented: 'Well I mean look everybody's scrambling, I know that. . .[toy company's] scrambling everywhere to be able to make it so that a nine dollar toy doesn't cost 19. And I think that our companies are, often, not given the credit that they deserve to be able to get things to move around, pull their weight, do things overseas, David, it's not like they're the only ones, China, that can make this stuff. Cause the stuff is not like, it's not like making a Grace Blackwell GB200 NVIDIA chip.' One material that's caught Cramer's attention is ethane. He believes that ethane's role in the plastics supply chain and the fact that China can't make it can enable the material to play a key role in President Trump's trade talks. Cramer commented: 'We have to focus on this ethylene, because it's the one thing that they're panicked on in China. They're not panicked on copper, they're panicked that they're not getting ethane, which makes ethylene, which makes plastic. Because boy do they ever make make plastic.' In fact, Cramer went as far as to 'advise' the President and his team to leverage US ethane production against China: 'But the building block of all that stuff is Louisiana, ethane. If the President and Navarros and these trade guys were to say, you know what guys, we saw that you wouldn't tariff ethane, cause you need it so bad, we're done, we're gonna ship it to Korea. Then see what happens. That's what they should do. That's like, free advice there.' As for the car industry, Cramer believes that Trump's advisor Peter Navarro won't be satisfied even if some car companies build their assembly plans in America. 'Peter Navarro would say over and over, we need the engines made we don't want the assembly,' he believes. Our Methodology To make our list of the stocks that Jim Cramer talked about, we listed down the stocks he mentioned during CNBC's Squawk on the Street aired on May 1st. For these stocks, we also mentioned the number of hedge fund investors. Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter's strategy selects 14 small-cap and large-cap stocks every quarter and has returned 373.4% since May 2014, beating its benchmark by 218 percentage points (see more details here).
